Zelboraf(vemurafenib)
Zelboraf (vemurafenib) is a small molecule pharmaceutical. Vemurafenib was first approved as Zelboraf on 2011-08-17. It is used to treat melanoma in the USA. It has been approved in Europe to treat melanoma. The pharmaceutical is active against serine/threonine-protein kinase B-raf. In addition, it is known to target RAF proto-oncogene serine/threonine-protein kinase.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Zelboraf
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| zelboraf | New Drug Application | 2024-11-08 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
VEMURAFENIB, ZELBORAF, HOFFMANN LA ROCHE | |||
| 2024-11-06 | ODE-158 | ||
HCPCS
No data
Clinical
Clinical Trials
171 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colorectal neoplasms | D015179 | — | — | 1 | 3 | 1 | — | — | 4 |
| Multiple myeloma | D009101 | — | C90.0 | — | 3 | 1 | — | — | 3 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | 3 | 2 | — | — | 3 |
| Hematologic neoplasms | D019337 | — | — | — | 3 | 2 | — | — | 3 |
| Thyroid neoplasms | D013964 | EFO_0003841 | — | — | 2 | 1 | — | — | 2 |
| Papillary thyroid cancer | D000077273 | — | — | — | 2 | 1 | — | — | 2 |
| Lung neoplasms | D008175 | — | C34.90 | — | 1 | 1 | — | — | 1 |
| Carcinoma | D002277 | — | C80.0 | — | 1 | 1 | — | — | 1 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 1 | 1 | — | — | 1 |
| Glioma | D005910 | EFO_0000520 | — | — | 1 | 1 | — | — | 1 |
Show 4 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | 2 | — | — | — | 2 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | — | 1 | — | — | — | 1 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 1 | — | — | — | 1 |
| Unknown primary neoplasms | D009382 | — | — | — | 1 | — | — | — | 1 |
| Plasma cell neoplasms | D054219 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Vemurafenib |
| INN | vemurafenib |
| Description | Vemurafenib is a pyrrolopyridine that is 1H-pyrrolo[2,3-b]pyridine which is substituted at position 5 by a p-chlorophenyl group and at positions 3 by a 3-amino-2,6-difluorobenzoyl group, the amino group of which has undergone formal condensation with propane-1-sulfonic acid to give the corresponding sulfonamide. An inhibitor of BRAF and other kinases. It has a role as an antineoplastic agent and a B-Raf inhibitor. It is a pyrrolopyridine, a sulfonamide, a member of monochlorobenzenes, a difluorobenzene and an aromatic ketone. |
| Classification | Small molecule |
| Drug class | rapidly accelerated fibrosarcoma (RAF) kinase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F |
Identifiers
| PDB | — |
| CAS-ID | 918504-65-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1229517 |
| ChEBI ID | 63637 |
| PubChem CID | 42611257 |
| DrugBank | DB08881 |
| UNII ID | 207SMY3FQT (ChemIDplus, GSRS) |
Target
Agency Approved
BRAF
BRAF
Organism
Homo sapiens
Gene name
BRAF
Gene synonyms
BRAF1, RAFB1
NCBI Gene ID
Protein name
serine/threonine-protein kinase B-raf
Protein synonyms
94 kDa B-raf protein, B-Raf proto-oncogene serine/threonine-protein kinase (p94), B-Raf serine/threonine-protein, murine sarcoma viral (v-raf) oncogene homolog B1, p94, Proto-oncogene B-Raf, v-raf murine sarcoma viral oncogene homolog B, v-Raf murine sarcoma viral oncogene homolog B1
Uniprot ID
Mouse ortholog
Braf (109880)
serine/threonine-protein kinase B-raf (P28028)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 17,481 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
12,697 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use